We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+7.75%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$19.9B
AUM Growth
+$1.62B
Cap. Flow
-$35.6M
Cap. Flow %
-0.18%
Top 10 Hldgs %
43.73%
Holding
208
New
17
Increased
41
Reduced
35
Closed
35

Sector Composition

Rank Sector Weight
1 Healthcare 35.32%
2 Technology 16.45%
3 Financials 12.17%
4 Industrials 7.23%
5 Communication Services 3.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VYGR icon
76
Voyager Therapeutics
VYGR
$201M
$14.8M 0.07%
1,292,000
+495,000
+62% +$5.12M
LSI
77
DELISTED
Life Storage, Inc.
LSI
$11.9M 0.06%
+89,794
New +$11.9M
COGT icon
78
Cogent Biosciences
COGT
$7.24B
$11.6M 0.06%
983,452
BRKR icon
79
Bruker
BRKR
$8.14B
$11.1M 0.06%
150,476
-344,000
-70% -$26.2M
SCRM
80
DELISTED
Screaming Eagle Acquisition Corp. Class A Ordinary Shares
SCRM
$10.3M 0.05%
1,000,000
RCM
81
DELISTED
R1 RCM Inc. Common Stock
RCM
$10.2M 0.05%
+552,000
New +$8.97M
RIO icon
82
Rio Tinto
RIO
$164B
$8.78M 0.04%
137,500
KCGI
83
DELISTED
Kensington Capital Acquisition Corp. V
KCGI
$8.19M 0.04%
775,200
ARYE
84
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
$7.71M 0.04%
745,000
LBPH
85
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$7.34M 0.04%
1,000,000
-560,500
-36% -$4.24M
CORS
86
DELISTED
Corsair Partnering Corporation
CORS
$7.26M 0.04%
700,000
EHC icon
87
Encompass Health
EHC
$12.4B
$6.77M 0.03%
+100,000
New +$6.27M
SLAM
88
DELISTED
Slam Corp. Class A Ordinary Share
SLAM
$6.1M 0.03%
570,396
BWC
89
DELISTED
Blue Whale Acquisition Corp I Class A Ordinary Shares
BWC
$5.84M 0.03%
575,000
VNET
90
VNET Group
VNET
$2.09B
$5.15M 0.03%
1,775,000
GHIX
91
DELISTED
Gores Holdings IX, Inc. Class A Common Stock
GHIX
$5.13M 0.03%
500,000
NTLA icon
92
Intellia Therapeutics
NTLA
$1.67B
$4.73M 0.02%
+116,000
New +$4.7M
TVRD
93
Tvardi Therapeutics
TVRD
$23.4M
$4.72M 0.02%
46,294
-9,133
-16% -$1.26M
FRXB
94
DELISTED
Forest Road Acquisition Corp. II
FRXB
$4.1M 0.02%
400,000
FSRX
95
DELISTED
FinServ Acquisition Corp. II Class A Common Stock
FSRX
$4.09M 0.02%
400,000
ISEE
96
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$3.93M 0.02%
+100,000
New +$3.53M
CITE
97
DELISTED
Cartica Acquisition Corp Class A Ordinary Shares
CITE
$3.73M 0.02%
350,000
APLS
98
DELISTED
Apellis Pharmaceuticals
APLS
$3.65M 0.02%
40,053
-277,500
-87% -$23.9M
UTAA
99
DELISTED
UTA Acquisition Corporation Class A Ordinary Shares
UTAA
$3.64M 0.02%
344,100
ALVO icon
100
Alvotech
ALVO
$1.29B
$3.38M 0.02%
437,110
-62,890
-13% -$585K

Similar funds

Farallon Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Farallon Capital Management held 208 positions worth $19.9B, up 8.8% from $18.3B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Farallon Capital Management's Q2 2023 filing shows 17 new, 41 increased, 35 reduced and 35 closed positions. Its largest new stake was Analog Devices: 2,075,000 shares worth $404M. The largest sale was Shaw Communications Inc., an estimated $473M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 33% a quarter earlier, followed by Technology and Financials.

  • Farallon Capital Management's largest Q2 2023 buy was Analog Devices: 2,075,000 shares worth $404M.
  • Farallon Capital Management added most to VMware, Inc in Q2 2023, an estimated $286M increase.
  • Farallon Capital Management's biggest Q2 2023 reduction was Salesforce, cutting an estimated $318M.
  • Farallon Capital Management fully exited Shaw Communications Inc. in Q2 2023, selling an estimated $473M.
  • Farallon Capital Management's ten largest holdings make up 44% of its $19.9B portfolio in Q2 2023.
  • Farallon Capital Management opened 17 new positions and closed 35 in Q2 2023.
  • Farallon Capital Management's portfolio value rose 8.8% quarter-over-quarter to $19.9B.

Based on Farallon Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.